PEI Respiratory Illness Summary 2023-2024 Season

Le contenu suivant est seulement disponible en anglais.

Week 14 – March 31 to April 6, 2024

The surveillance period for the 2023-24 PEI Respiratory Illness Summary starts from August 27, 2023 (epidemiological week 35-2023) to August 24, 2024 (epidemiological week 34-2024).  Surveillance weeks correspond to the Public Health Agency of Canada (PHAC) influenza surveillance weeks. While COVID-19 is not yet recognized as a seasonal respiratory virus, unlike influenza and RSV, data for COVID-19 are reported according to the surveillance period established for influenza.

Summary

  • COVID-19 detections decreased with 5 new cases being reported between March 31 to April 6, 2024
  • Influenza detections decreased with 17 new lab-confirmed influenza cases reported 
  • RSV detections remained stable with 4 new lab-confirmed RSV cases reported 
  • COVID-19 test positivity decreased to 3.7%, influenza test positivity decreased to 12.2%, and RSV test positivity remained stable at 2.9%
  • Number of Paxlovid dispenses: 10
  • Number of new hospital admissions for COVID-19: 3
  • Number of new hospital admissions for influenza: 1
  • Number of new hospital admissions for RSV: 0
  • Number of deaths due to COVID-19 reported to the Chief Public Health Office: 0
  • Number of deaths due to influenza reported to the Chief Public Health Office: 0
  • Number of deaths due to RSV reported to the Chief Public Health Office: 0
  • Number of new respiratory outbreaks: 0

 

Epidemiological curve and test positivity

Weekly respiratory illness case count and test positivity by respiratory virus, PEI 2023-24 surveillance period

Epi_curve April 9

                                                                  Current Reporting Period (Mar 31 to Apr 6, 2024) Previous Reporting Period (Mar 24 to Mar 30, 2024) Cumulative 2023-24 Surveillance Period
  Case Counts Test Positivity Case Counts Test Positivity Case Counts     
COVID-19            5       3.7      14      7.0       1,122
Influenza      17      12.2      47      24.4        792
RSV       4       2.9       5       2.0        401

 

 

 

 

 

 

 

 

 

 

 

PAXLOVID Dispenses, current period, previous period, and cumulative in 2023-24 

Paxlovid is an anti-viral treatment for individuals at higher risk of more severe outcomes, such as hospitalization, and who do not have any contraindications for the treatment.  For information on eligibility and how to access Paxlovid, visit: https://www.princeedwardisland.ca/en/information/health-and-wellness/caring-for-yourself-or-others-with-covid-19 

  Current Reporting Period
(Mar 31 to Apr 6, 2024)
Previous Reporting Period
(Mar 24 to Mar 30, 2024)
Cumulative 2023-24 Surveillance Period
Number of Paxlovid dispenses         10         18         2,318

 

Respiratory Illness outbreaks, current period, previous period, and cumulative in 2023-24 

  Current Reporting Period
(Mar 31 to Apr 6, 2024)

Previous Reporting Period (Mar 24 to Mar 30, 2024)

Cumulative 2023-24 Surveillance Period
  LTC/CC1 Other2 LTC/CC1 Other2 LTC/CC1  Other2
COVID-19      0      0      0      0      48      6
Influenza      0      0      0      0      12      0
RSV      0      0      0      0       4      0
ILI      0      0      0      0       0      2
Mixed Pathogen      0      0      0      0       0      0

 

 

 

 

 

 

 

 

 

 

1 LTC = long term care facility; CC = community care facility
2 For example, acute care facilities and correctional facilities
ILI = influenza like illness

Severe outcome surveillance,current period, previous period, and cumulative in 2023-24

  Current Reporting Period
(Mar 31 to Apr 6, 2024)
Previous Reporting Period (Mar 24 to Mar 30, 2024) Cumulative 2023-24 Surveillance Period
COVID-19

        

   
  •  Hospitalizations
       3          4         98
  •  ICU
       1          0           6
  •  Deaths
       0          0         15
INFLUENZA      
  •  Hospitalizations
       1          1        117
  •  ICU
       0          0         17
  •  Deaths
       0          0           8
RSV      
  • Hospitalizations
       0         1        103
  •  ICU
       0         0           3
  • Deaths
       0         1           3

 

Surveillance for COVID-19 Variants

PEI contributes data to the national reporting of COVID-19 variants in Canada

 

Wastewater Surveillance 

PEI’s Chief Public Health Office and the Department of Environment, Energy and Climate Action have partnered with the municipalities of Alberton, Charlottetown (including Stratford), Montague, Souris, and Summerside, and the National Microbiology Laboratory in Winnipeg to implement wastewater surveillance for COVID-19 in PEI.
PEI wastewater testing results are included on the national COVID-19 wastewater surveillance dashboard
 

Historical COVID-19 Data

Year Total Cases Hospitalized ICU Deaths
2023 to Week 34 1,727 112 7 28
2022 54,179 355 29 81
2021 1,413 5 1 0
2020 96 0 0 0

Historical Influenza Data

Influenza Season Predominant Strain Total Cases Hospitalized ICU Deaths
2022-23 A/H3 360 78 7 5
2021-22 A/H3 66 12 1 0
2020-21 - 0 0 0 0
2019-20 A 220 77 7 5
2018-19 A/pH1N1 280 123 12 9
2017-18 B 319 132 13 6
2016-17 A/H3 208 88 11 5
2015-16 A/pH1N1 71 39 2 1
2014-15 A/H3 (B) 209 98 11 9
2013-14 A/pH1N1 119 62 13 2

 

Technical Notes

COVID-19 case count includes individuals who tested positive on lab-based PCR, Abbott ID Now NAAT, and Lucira NAAT.  It does not include individuals that tested positive on a rapid antigen test.

Note that clinical diagnosis of influenza takes place frequently in the community during peak season and is not confirmed with laboratory testing. In contrast to COVID-19, the prescribing of anti-viral treatment for influenza does not require a positive influenza test and can be based on a clinical diagnosis alone. Given the differences in testing approaches, the number of influenza detections and the number of COVID-19 detections in a given time period are not directly comparable.

COVID-19, influenza and RSV case counts are just an indication of greater respiratory illness activity as many individuals with respiratory illness do not seek medical attention.

Test positivity = (Count of positive tests per reporting period) / (Count of total tests per reporting period)  ×100

Test positivity for COVID-19 includes lab-based PCR and Abbott ID Now NAAT.  For influenza and RSV, test positivity includes lab-based PCR. Cases among PEI residents diagnosed outside of the province are included in the case counts but are excluded from the percent positivity calculation.

Paxlovid dispenses will only be reported when there’s at least 10 dispenses during the reporting period.


Outbreak definitions
    -Influenza

  • Laboratory-confirmed influenza outbreak: two or more cases of influenza like illness (ILI) within a seven-day period with an epidemiological link, including at least one laboratory confirmed case of influenza within a surveillance setting
  • ILI outbreak: two or more cases of ILI within a seven-day period
  • ILI outbreak in school or workplace: Greater than 10% absenteeism which is likely due to ILI

    -COVID-19 outbreak

  • 2 or more test-confirmed cases of COVID-19 which are epidemiologically linked to a specific setting or location

    -RSV

  • 2 or more cases of ILI within a seven-day period with an epi link, including at least one laboratory confirmed case of RSV within a surveillance setting

Hospitalization definition: a laboratory confirmed case of influenza/RSV or test-confirmed case of COVID-19 that received treatment in hospital as a result of their respiratory illness

ICU admission definition: a case of influenza, RSV or COVID-19 that meets the hospitalization definition and was admitted to the ICU

Death definition: a death resulting from a clinically compatible illness in a laboratory confirmed influenza/RSV case or test-confirmed COVID-19 case. A death due to influenza/COVID-19/RSV may be attributed when influenza/COVID-19/RSV is the cause of death or is a contributing factor. 

Test-confirmed COVID-19 case: case with a positive result on lab-based PCR, Abbott ID Now NAAT, or Lucira NAAT.  A case with a positive result on a rapid antigen test may be considered to be a test-confirmed case of COVID-19 upon review by a Chief Medical Officer of Health or relevant public health authority.  

Hospitalization data is gathered through infection prevention and control practitioners at each Island hospital.

Hospitalizations, ICU admissions, and deaths are reported based on the date that they are reported to the Chief Public Health Office.

Data presented throughout the report may be updated retroactively as new data becomes available.
 

Date de publication : 
le 10 Avril 2024
Santé et Mieux‑être

Renseignements généraux

Ministère de la Santé et du Mieux-être
Immeuble Shaw, 4e étage (nord)
105, rue Rochford
Charlottetown (Î.-P.-É.) C1A 7N8

Téléphone : 902-368-6414
Télécopieur : 902-368-4121

DeptHW@gov.pe.ca